GTX-102 Phase 1/2 Trial: First patient dosed in Canada

Another exciting update from GeneTx and Ultragenyx today, 7th October announcing that the Phase 1/2 Clinical Study of GTX-102 in Canada has now begun. First preliminary results will be available towards the end of the year and the end of this phase is anticipated in the middle of 2022 following the 128 days period of trial participation.

Read the full press release here.